Expanding on the theme that CD40 stimulation and PRR stimulation can be additive or synergistic but could be limited by cytokine-mediated toxicity, intratumoral delivery of a TLR7 agonist along with systemic CD40 stimulation has been shown to be effective in a murine model of mesothelioma [48, 49]. The gene discussed is CD40; the disease is mesothelioma.